Trial Profile

A Phase 1B Dose Escalation, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-hodgkin's Lymphoma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 02 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CC 95775 (Primary)
Indications Adenoid cystic carcinoma; Basal cell cancer; Chondrosarcoma; Chordoma; Malignant melanoma; Non-Hodgkin's lymphoma; Solid tumours
Focus Adverse reactions
Sponsors Celgene Corporation

31 Jan 2022 Status changed from active, no longer recruiting to completed.
18 Aug 2021 Planned End Date changed from 31 Aug 2021 to 31 Oct 2021.
18 Aug 2021 Planned primary completion date changed from 5 Jul 2021 to 31 Oct 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com